Insider selling and analyst updates put Privia Health Group (PRVA) in focus
Privia Health Group (PRVA) is back on investor radar after Chief Financial Officer David Mountcastle sold 5,566 shares, followed by a fresh round of analyst updates after the company’s Q4 earnings release.
See our latest analysis for Privia Health Group.
At a share price of $22.38, Privia Health Group has seen short term momentum pick up, with a 1 day share price return of 3.66% and a 7 day share price return of 8.80%. At the same time, the 1 year total shareholder return sits at 2.94% and the 3 year total shareholder return at a loss of 20.24%. This suggests confidence has firmed recently after the Q4 earnings update and insider activity, while longer term holders have had a more muted experience.
If you are weighing Privia against other healthcare names using technology in care delivery, this could be a good moment to scan a dedicated list of 37 healthcare AI stocks
With the shares trading at $22.38, a reported intrinsic discount of about 47% and a sizable gap to the average analyst target, you now have to ask: is Privia undervalued, or is the market already pricing in future growth?
Most Popular Narrative: 30% Undervalued
Against the last close at $22.38, the most followed narrative points to a fair value of $31.95, implying a sizeable valuation gap that hinges on future earnings power.
The industry wide movement towards value based care, with associated shared savings and care management fees, is enabling Privia to grow its value based attributed lives at a double digit rate and to expand margins as risk sharing agreements mature, positively impacting earnings and long term EBITDA growth.
Want to see what is baked into that gap between price and fair value? The narrative leans heavily on faster earnings growth, richer margins and a punchy future earnings multiple.
Result: Fair Value of $31.95 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, investors still need to weigh risks such as tightening insurer and hospital bargaining power, as well as higher labor or compliance costs that could pressure margins and contract terms.
Find out about the key risks to this Privia Health Group narrative.
Another angle: market multiple sends a different signal
The fair value narrative points to upside, yet the current P/E of 122.7x is far above both the peer average of 28.9x and a fair ratio of 28.4x. That gap suggests investors are paying a very rich price today. This raises the question of whether the perceived opportunity is already reflected in the share price.
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
With sentiment clearly mixed, this is a moment to move quickly, review the facts for yourself, and weigh both sides of the story using our 4 key rewards and 1 important warning sign
Looking for more investment ideas?
If you stop with a single stock, you miss the chance to compare, pressure test your thinking, and spot ideas that might fit your goals even better.
- Spot potential value opportunities early by scanning companies that appear mispriced on quality and fundamentals using the 61 high quality undervalued stocks.
- Prioritise resilience by reviewing businesses that show stronger balance sheets and fundamentals through the solid balance sheet and fundamentals stocks screener (40 results).
- Hunt for fresh opportunities off the beaten path with the screener containing 25 high quality undiscovered gems before the crowd catches on.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com